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Abstract
Background: Ataxia Telangiectasia (A-T) is a rare monogenetic neurodegenerative disease with pulmonary,
nutritional, and dysphagic complications. Gastrostomy tube (GT) feedings are commonly recommended to manage
these co-morbidities. In general, outcomes of GT placement in patients with progressive diseases that develop
during childhood are not well characterized. The primary purposes of this study were to determine whether GT
placement in patients with A-T would be tolerated and associated with caregiver satisfaction.
Methods: We completed a retrospective review of 175 patients who visited the A-T Children’s Center at Johns
Hopkins Hospital from 2001 through 2008, and identified 28 patients with A-T (19 males, 9 females) who
underwent GT placement for non-palliative reasons. Information was obtained from medical records, interviews
with primary health care providers, and 24 (83%) caregivers of patients with GT’s who responded to survey
requests.
Results: Twenty-five (89%) patients tolerated GT placement and were a median of 5.0 (0.4-12.6) years post GT
placement at the time of this investigation. Three (11%) patients died within one month of GT placement. In
comparison to patients who tolerated GT placement, patients with early mortality were older when GT’s were
placed (median 24.9 vs. 12.3 years, p = 0.006) and had developed a combination of dysphagia, nutritional, and
respiratory problems. Caregivers of patients tolerating GT placement reported significant improvements in
mealtime satisfaction and participation in daily activities.
Conclusions: GT placement can be well tolerated and associated with easier mealtimes in patients with A-T when
feeding tubes are placed at young ages. Patients with childhood onset of disorders with predictable progression of
the disease process and impaired swallowing may benefit from early versus late placement of feeding tubes.
Background
Ataxia Telangiectasia (A-T) is a rare neurodegenerative
disease characterized by ataxia, immunodeficiency, sino-
pulmonary infections, premature aging, nutritional com-
promise and oropharyngeal dysphagia[1-6]. The
prevalence of A-T is estimated to be between 1 in
40,000 and 1 in 300,000 live births[7-9]. Life expectancy
has increased from 19 to 25 years, with respiratory fail-
ure, complications of chemotherapy or cancer, and neu-
rologic deterioration remaining the leading causes of
death[10]. Increased morbidity and mortality is asso-
ciated with impairments in deglutition, nutritional
status, immune function, and neurologic status in other
chronic progressive conditions [11-14]. Treatments that
improve nutritional status and minimize the risk of
aspiration for patients with chronic progressive disorders
are salutary[15-20]. Thus it is important to provide
information that guides clinicians in the selection of
interventions for nutrition and aspiration induced lung
injury with progressive conditions.
Gastrostomy tube (GT) feedings are commonly used
to manage dysphagia with concomitant aspiration, or
manage chronic conditions associated with nutritional
compromise that are refractory to less aggressive adjust-
ments in feeding routine[18,21-23]. Nonetheless, out-
comes associated with GT placement are mixed.
Whereas some investigators report that GT placement
leads to significant improvements in growth and health
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parameters and caregivers’ perceptions,[2,15,18,24-27]
others have cautioned about adverse outcomes and
questioned whether available evidence supports the cost
and effectiveness of GT[28-30]. In our experience, this
controversy frequently results in postponing the place-
ment of feeding tubes, particularly when GT placement
is perceived as a measure of last resort.
The national clinical center for A-T at the Johns Hop-
kins Clinical Center (ATCC) attracts a large cohort of
patients and afforded the opportunity to identify clinical
characteristics associated with outcome following GT
placement. We hypothesized that GT placement would
be well tolerated and viewed positively by both care-
givers and patients with A-T. Our secondary goals were
to elucidate clinical characteristics of patients who
would benefit from feeding tubes and improve our
understanding of when to recommend placement of
feeding tubes.
Methods
Between October 2001 and September 2008, 175
patients with A-T were evaluated at the Johns Hopkins
ATCC. Criteria for a diagnosis of A-T included the pre-
sence of characteristic neurologic features (gait ataxia,
oculomotor dysfunction, dysarthria, and a movement
disorder) and at least one of the following: oculocuta-
neous telangiectasia, elevated serum levels of alpha-
fetoprotein, or spontaneous or x-irradiation-induced
chromosomal breakage[31]. We identified patients who
had GT’s placed before or after clinic visits to our cen-
ter. The A-T Children’s Project (an organization dedi-
cated to patient support and research) identified
additional patients who had GT’s placed after their visits
to our center. Between July 2005 and September 2008,
the nurse coordinator at the ATCC contacted caregivers
of all patients who were identified as having GT’s placed
before May 2008. Each caregiver was asked to complete
a survey on caregiver and patient satisfaction pre- and
post-GT placement. (Additional File 1) The nurse coor-
dinator followed up with phone calls to caregivers and
read survey questions to any caregivers who requested
help to complete the survey. Demographic information,
pre-GT BMI Z-scores, neurologic scores, dysphagia and
immunologic status, reason for GT placement, and
cause of death information were obtained from medical
records and follow up calls to the offices of primary
health care providers. Survival data were collected
through September 2008, 4 months or longer after GT
placement. Pre-GT BMI Z-scores were obtained less
than two years before GT placement. Neurologic scores
were calculated from the Quantitative Neurologic
Assessment of Ataxia Telangiectasia index within two
years of GT placement[4]. Lower neurologic scores are
associated with greater disease progression. Dysphagic
problems were determined by clinical presentations and
videofluoroscopic swallow study examinations as pre-
viously described[3]. The protocol for this study was
approved by the Institutional Review Board of The
Johns Hopkins Medical Institution.
Statistical Analysis
Patients were categorized as tolerating GT placement if
they survived 30 or more days following GT placement.
Patients who survived less than 30 days after GT place-
ment are henceforth referred to as patients with early
mortality. Fisher’s exact tests and Wilcoxon rank sum
tests were used to compare patient characteristics of
those who tolerated GT placement and those with early
mortality. Pearson correlation was used to assess the
association of neurologic score and age at time of GT
placement. Because of the limited sample size, we used
univariable logistic regression analysis with Firth’s bias
correction for continuous measures and exact methods
for categorical measures to determine factors associated
with tolerating GT placement. Pre- and post-GT BMI z-
scores were compared using Wilcoxon signed rank test.
Mealtime satisfaction and energy to participate in daily
activities pre- and post-GT placement were compared
using paired t-tests. Statistical analysis was performed
using SAS version 9.2 (SAS Institute, Inc., Cary, NC).
All P values reported are two-sided and statistical signif-
icance was set at p < 0.05.
Results
Twenty-nine patients with A-T were identified from our
outreach and chart review as having undergone GT place-
ment (Figure 1). Chart reviews were completed on average
4.11 years (median, range: 3.58, 0.28-11.16 years) after GT
placement. One of these patients underwent GT place-
ment specifically for palliative care and was excluded from
the analysis. Individual patient characteristics for the
28 patients included are described in Table 1. The median
(range) age at the time of GT placement was 12.6 years
(4.6-27.0 years), 19 (68%) were male and 9 (32%) were
female. All patients had GT placed for nutrition support
and 12 (43%) also had dysphagia.
Twenty-five (89%) patients survived more than 30 days
after the procedure. Patients tolerating GT placement
had feeding tubes placed at a median (range) age of 12.3
(4.6-17.0) years and at the time of our retrospective
assessment were 5.0 (0.4-12.6) years post tube placement.
At the time of this investigation, 16 (64%) of patients
tolerating GT placement, were alive. The mean age of
death was 19.5 ± 4.3 years for those who tolerated GT
placement but were deceased at the time of this investi-
gation. Respiratory problems were the leading cause of
death and occurred in 6 (67%) of these patients; five
(56%) of the deaths were attributed to cancer or other
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non-respiratory conditions. (Table 1) At the time of data
collection, median post GT survival times were margin-
ally shorter for those who tolerated GT placement and
were alive versus deceased (4.3 [0.4-12.6] vs. 6.3 [4.5-
11.1] years, p = 0.05).
Three (11%) patients died within one month of GT
insertion. In comparison to patients who tolerated GT
insertion, these patients were significantly older when
GT’s were placed. (Table 2) Although there were an
insufficient number of patients to demonstrate statistical
significance, each had significant weight loss, dysphagia,
and severe respiratory problems. Two patients with
early mortality lost more than 10 pounds during the
year preceding GT placement and one of these patients
had an FVC of 20% predicted. (Table 1)
Age of GT placement was marginally correlated with
neurologic score (Pearson’s r = -0.33; p = 0.08). (Figure 2)
Age of GT placement was associated with tolerating GT
placement (OR = 0.62; 95% confidence interval (CI) =
0.41-0.94); for each year increase in age there was a 38%
decrease in the odds of tolerating GT placement. Factors
examined that were not statistically significant for associa-
tion with tolerating GT placement were male gender
(OR = 4.81; 95% CI = 0.22-319.8), dysphagia (OR = 0.27;
95% CI = 0.00-2.69), neurologic score (OR = 1.02; 95%
CI = 0.96-1.08 for a 1 unit increase) and BMI Z-score
(OR = 1.11; 95% CI = 0.78-1.57 for a 1 unit increase).
(Table 3) Pre-GT BMI Z-scores were obtained less than
two years (median: 0.50 years, range: 0.08 to 1.40 years)
before GT insertion for 16 patients tolerating tube place-
ment. The median pre-GT BMI Z-score for these
16 patients was -3.82 (range: -11.89 to 0.90). The median
post-GT BMI Z-score from anthropometric data obtained
on 17 patients at a median of 2.57 years (range: 0.45 to
Figure 1 Population derivations.
Lefton-Greif et al. Orphanet Journal of Rare Diseases 2011, 6:23
http://www.ojrd.com/content/6/1/23
Page 3 of 10
























Patients tolerating GT placement
1 F 10 <1 No Normal Deficient Nutrition Yes
2 M 15 <1 -1.76 35 Yes: P Deficient Normal Nutrition, GER treated w/
nissen fundoplication
Yes
3 M 6 1 0.90 No Normal Deficient Nutrition, GER, pulmonary
infections
Yes
4 F 10 1 -6.23 68 No Normal Deficient Nutrition Yes
5 M 12 1 -2.77 51 No Deficient Normal Nutrition Yes
6 F 13 1 Yes: P Normal Normal Nutrition, dysphagia Yes
7 F 15 1 -0.44 40 No Deficient Deficient Nutrition Yes
8 M 15 1 -5.72 36 No Normal Normal Nutrition, dysphagia Yes
9 M 10 2 -8.17 59 No Deficient Normal Nutrition Yes
10 M 10 3 No Deficient Normal Nutrition, cancer Yes
11 M 13 3 -0.65 38 Yes: P Deficient Normal Nutrition, LL pneumonia Yes
12 M 10 4 -4.25 32 Yes: A Deficient Normal Nutrition, dysphagia Yes
13 M 14 4 -4.42 22 Yes: A Deficient Normal Nutrition, dysphagia Yes
14 M 16 4 41 Yes: A Deficient Normal Nutrition, dysphagia No Leukemia, lung
complications
15 M 10 5 -0.79 47 Yes: A Deficient Deficient Nutrition, dysphagia No Burkitt lymphoma;
lung complications;
recurrent aspiration
16 F 12 5 -7.57 39 Yes: P Deficient Normal Nutrition, dysphagia No Lung complications,
failure to thrive,
recurrent aspiration
17 M 13 5 -3.39 53 Yes: P Deficient Deficient Nutrition, dysphagia Yes
18 M 15 6 No Deficient Normal Nutrition No Non-Hodgkin
Lymphoma T cell
19 M 17 6 Yes: A, R Deficient Normal Nutrition No Aspiration
pneumonia
20 M 5 8 No Normal Deficient No Hodgkin lymphoma
21 F 11 8 -3.12 35 No Normal Normal Nutrition Yes
22 M 17 8 -5.03 21 Yes: P, R Normal Normal Nutrition, dysphagia No T-Cell Lymphoma,
lung complications
23 M 7 9 No Deficient Normal Nutrition Yes
24 M 15 9 -11.89 19 Yes: P Deficient Deficient No Congestive heart
failure




Patients with early mortality following GT placement
1 F 22 0 -7.03 50 Yes: P, R Normal Normal Nutrition (10 lb weight loss/3
yrs), dysphagia, recurrent
pneumonia








Nutrition (10 lb weight loss/1
yr), dysphagia, chronic cough,
declining respiratory function
(FVC = 20% predicted)




3 M 27 0 -7.78 15 Yes: P, R Deficient Normal Nutrition (16 lb weight loss/1
yr), dysphagia




1BMI Z-scores were obtained less than 2 years before GT placement.
2A-T neurologic scores were obtained less than 2 years before or after GT placement
3Dysphagia was defined as Videofluoroscopic Swallow Study findings of Penetration (P), Aspiration (A) or Post-Swallow Residue (R).
Abbr: BMI, body mass index
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5.79 years) after tube placement was -1.17 (range: -11.15
to 1.54). Pre- and post-GT BMI Z-scores were available
on 10 patients, and the median change was 0.87 (range:
-3.58- 6.72; Wilcoxon signed rank p = 0.32). BMI Z-scores
improved or remained stable for seven (70%) patients and
decreased in 3 (30%) patients after GT placement. (Figure
3) GT’s were not used in two patients as recommended.
Caregivers did not administer GT feedings for the patient
with a decreased BMI-Z score after GT placement and the
second patient chose to not use the GT. Early mortality
was not predicted by BMI Z-score alone. Gender, IgA,
IgG, and presence of dysphagia were comparable for
patients tolerating GT placement and those with early
mortality. Minor post-GT complications included wound
infection in 1 (4%) patient, tube dislodgement in 1 (4%)
patient, and wound leakage in 9 (36%) patients.
All of the 24 (86%) responders to our survey were
caregivers of patients who tolerated GT placement and
15 (54%) were caregivers of patients who were alive at
the time of this study. Responders were more likely to
be caregivers of patients with GT’s placed at younger
versus older ages (mean age: 12.7 vs. 20.2 years, p =
Table 2 Demographic and clinical characteristics for patients tolerating gastrostomy tube (GT) placement and patients
with early mortality after GT placement
Characteristics Patients tolerating GT placement
(n = 25)
Patients with early mortality
(n = 3)
P value*
Male sex, N (%) 18 (72) 1 (33) 0.23
Age at GT placement, years, median (range) 12.3 (4.6-17.0) 24.9 (22.1-27.0) 0.006
Neurologic score, median (range) 41 (19-77) 50 (15-53) 0.55
Body mass index for age, median (range) -3.82 (-11.89-0.90)a -7.03 (-7.78- -1.10) 0.47
IgA deficient, N (%) 17 (68) 0 (0) 0.13
IgG deficient, N (%) 8 (32) 0 (0) 1.0
Dysphagia, N (%) 12 (48) 3 (100) 0.23
* P value from Fisher’s exact test or Wilcoxon rank sum test.
a Data only available on 16 of the 25 patients.
Figure 2 A-T neurologic score and age of GT placement. Gray dots represent A-T neurologic scores for all 347 patients with A-T who were
evaluated at the ATCC. Blue crosses represent the A-T patients who tolerated GT placement. Red circles represent the three patients with early
mortality.
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0.02). Caregivers reported significant improvements in
mealtime satisfaction and energy levels for participation
in daily activities after GT placement. (Figure 4) Care-
givers and patients viewed tube feedings as usually easy
to administer and caregivers were almost always satisfied
with having the GT’s placed.
Discussion
This retrospective study demonstrates that safe GT pla-
cement and caregiver satisfaction can be achieved when
patients with A-T have feeding tubes placed at younger
ages and before the accumulation of severe complica-
tions associated with nutritional compromise or dyspha-
gia with concomitant aspiration. Therefore, we
recommend GT’s when patients with A-T are young
and begin to present with nutrition, respiratory, and
dysphagic compromises that are unresponsive to com-
mon conservative measures (e.g., dietary modifications
and medical therapies) or when feeding disrupts activ-
ities of daily living. Although A-T is a rare and complex
disease, these findings may have clinical relevance to
other children and young adults with neurodegenerative
conditions being considered for GT placement.
Survival for patients with A-T has increased with good
quality care[10]. Our study was not designed to evaluate
the impact of GT’s on life expectancy. Longitudinal stu-
dies are needed to determine whether early GT place-
ment improves survival. Nonetheless, GT placement is
likely to be beneficial for some patients with A-T and
we believe that this investigation shows that safety of
GT placement can be improved.
At the time of this investigation, our patients who tol-
erated GT placement had feeding tubes for a median of
5.04 years and approximately two-thirds of them were
alive. Those who expired lived to an average age of 20
years, comparable to previously reported survival data
[10]. Causes of death were cancer or complications of
cancer (55%), congestive heart failure (22%), and respira-
tory complications including aspiration (22%). Therefore
more than half of the deaths among those who tolerated
GT insertion were related to conditions or processes
unlikely to be influenced by placement of a feeding
tube. We continue to follow surviving patients to ascer-
tain the long term impact of GT placement. Given that
many factors influence survival we will focus on mea-
sures, such as weight gain and stability, frequency of
respiratory tract infections, and the onset of dysphagic
presentations. Additionally, we will track changes in the
ability to participate in daily routines that are most
directly related to GT placement. The latter outcome is
a key factor in the quality of life of those increased sur-
vival years.
Three (11%) patients died within 30 days of GT place-
ment. (Table 1) None of these patients had GT’s placed
at a tertiary care center. Although our 30-day mortality
rate was comparable to the 0 - 27% mortality rates
reported in other populations undergoing GT insertion
[2,17,21,32,33], the differences between those who toler-
ated GT placement and those with early mortality are
substantial. The three with early mortality had GT’s
placed at older ages and all demonstrated co-morbidities
associated with poor outcomes with GT placement that
have been identified in other patient populations with
progressive conditions including advanced lung disease,
malnutrition, aspiration, and immune deficiency
[18,30,32,34-36]. Nonetheless, their immunoglobulin
levels, BMI, and neurologic scores did not significantly
differ from those who tolerated GT placement. Postpon-
ing GT placement as long as possible in patients with
A-T may not be in a patient’s best interest. Minor com-
plication rates were comparable to the wide range of 6 -
95% previously reported[2,21,32,33,37].
Despite efforts to place GT’s at younger ages and
before the development of significant co-morbid condi-
tions, some of our patients present to clinic when they
are older and have developed risk factors associated
with poor outcomes in other patient populations[11-14].
For these patients, we recommend evaluations and inter-
ventions that may help minimize complications includ-
ing nutritional rehabilitation when needed [38-40] and
initiation of necessary pulmonary interventions before
GT placement[39-41]. Due to the increased risk of com-
plications in all patients with A-T, we recommend pla-
cement of GT’s at a tertiary medical care center.
Table 3 Unadjusted odds ratios and 95% confidence intervals for surviving greater than 30 days after gastrostomy
tube (GT) placement by patient characteristics.
Surviving greater than 30 days after GT placement
Characteristic Odds Ratio 95% Confidence Interval P value
Male gender 4.81 0.21 - 319.8 0.47
Age at GT placement, 1 year increase 0.62 0.41 - 0.94 0.02
Dysphagia 0.27 0 - 2.69 0.28
Neurological z-score, 1 point increase 1.02 0.96 - 1.08 0.58
BMI for age, 1 unit increase 1.11 0.78 - 1.57 0.58
Abbr: BMI, body mass index
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Additionally, the risk and benefits of GT placement
should be discussed with the patient and guardian.
Those with more significant lung pathology, including
an abnormal chest x-ray, compromised pulmonary func-
tion, the need for bronchodilators, older age and
concurrent other medical problems may be at higher
risk for pulmonary complications during anesthesia
[42,43]. Post-operatively, a slow re-introduction of feeds
to minimize feeding intolerance, and prompt weaning
from mechanical ventilation and early extubation may
Figure 3 BMI Z-scores before and after GT placement. Blue circles represent individual patients who tolerated GT placement and used GT’s.
Green diamonds represent the two patients who tolerated GT placement but did not use their feeding tubes. Red squares represent the three
patients with early mortality. Percentile BMI Z-score is based on NHANES normal values for age and gender. For patients older than 20 years,
percentile BMI Z-scores were based upon NHANES normal values for the age of 19 years 11 months and gender. Source for BMI calculations:
http://statcoder.com/
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minimize complications associated with underlying
respiratory disease in patients with A-T[44].
Caregiver’s were very satisfied with GT’s and reported
that patients had more energy to participate in daily
activities. Our results are comparable to other reports of
meals being easier and more enjoyable for caregivers
and patients alike[2,23,27]. Nonetheless, one of the lim-
itations of this study was that all respondents were care-
givers of patients who tolerated GT placement.
Additionally, it is possible that satisfied caregivers were
more likely than displeased caregivers to respond to our
inquiries and that recollection bias may have played a
role in their responses. Another potential limitation is
that the survey was comprised of descriptive terms that
were not defined precisely and may have been open to
variable interpretation.
Many of the limitations of this investigation can be
attributed to the retrospective study design and small
sample size. For example we were unable to determine
the impact of GT feedings on nutritional status because
our data did not allow us to standardize the timing of
anthropometric measures before and after GT placement,
verify whether all patients used GT’s as recommended,
and obtain complete sets of comparable data for all
patients. Additionally the natural course of anthropo-
metric changes associated with disease progression has
not been characterized. The small sample size (e.g., three
patients in the early mortality group) may contribute to
possible discrepancies between findings of clinical and
statistical significance. Available records did not permit
identification of a control group of patients who did not
undergo the procedure despite our recommendations for
GT placement. It is notable that GT placement had been
recommended for several years prior to their eventual
placement in the three patients with early mortality. Dur-
ing the interval between the initial recommendation for
GT placement and tube insertion, nutrition and respira-
tory compromises increased for these three patients. Pro-
spective investigations that track markers of respiratory
and nutrition status pre- and post-GT placement are
needed to facilitate decision making for determining
when GT’s should be placed.
Conclusions
In conclusion, improved safety and easier mealtimes
appear to be achievable for A-T patients when GT’s are
placed at young ages. It is our hope that early GT place-
ment will decrease the severe complications associated
with nutritional insufficiency and aspiration secondary
to dysphagia. While we are unable to define the optimal
age for GT placement, improved outcomes are contin-
gent upon limiting the impact of adverse risk factors
Figure 4 Mealtime satisfaction and energy to participate in daily activities before and after GT placement. All pre-post GT comparisons,
p < 0.0001
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generally associated with GT placement as well as those
associated with characteristics of the specific disease
process. Patients with childhood onset of disorders with
predictable progression of the disease process and
impaired swallowing may benefit from early versus late
placement of feeding tubes.
Additional material
Additional file 1: Caregiver Survey.
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